Drug Profile
Research programme: antiviral and antibacterial monoclonal antibody therapeutics - Valneva
Alternative Names: Antiviral and antibacterial mAbs- Valneva; Antiviral and antibacterial monoclonal antibodies - Valneva; mAb D 005Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Intercell
- Developer Valneva
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Bacterial infections; Cytomegalovirus infections; Influenza virus infections; Streptococcal infections
Highest Development Phases
- No development reported Bacterial infections; Cancer; Cytomegalovirus infections; Influenza A virus infections; Streptococcal infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bacterial-infections in Austria (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Austria (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cytomegalovirus infections in Austria (Parenteral)